Clinical Trials Sponsored by Genmab

Total 1224 results

Genmab

Recruiting

A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma | Classical Hodgkin Lymphoma

United States, Australia
Genmab

Recruiting

GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies

Acute Myeloid Leukemia (AML) | Diffuse Large B Cell Lymphoma (DLBCL) | Relapsed or Refractory Multiple Myeloma (RRMM)

United States, Korea, Republic of, Netherlands, Denmark, Australia, New Zealand, Poland, Spain, Sweden, Czechia, Malaysia, Greece, Moldova, Republic of, Georgia, Ukraine, France, Hungary, North Macedonia
Genmab

Completed

Zalutumumab in Non-curable Patients With SCCHN

Head and Neck Cancer | Squamous Cell Cancer

United States, Germany, Israel, Colombia, Czechia, Austria, Chile, Italy, Peru, Portugal, Slovakia
Genmab

Completed

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

Melanoma | Sarcoma | Cervical Cancer | Ovarian Cancer | Endometrial Cancer | Solid Tumors | Thyroid Cancer | Non Small Cell Lung Cancer (NSCLC)

United States, United Kingdom, Belgium, Denmark, Netherlands, Spain
Genmab

Terminated

Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer (GEN206)

Colorectal Cancer

Belgium
Genmab

Completed

Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.

Cutaneous T-Cell Lymphoma

United States
Genmab

Recruiting

GEN1047 for Solid Tumors - First in Human (FIH) Trial

Squamous Non Small Cell Lung Cancer (NSCLC-SCC) | Breast Cancer, Breast Neoplasms | Endometrial Cancer, Endometrial Neoplasm | Ovarian Cancer, Ovarian Neoplasms

United States, France, Spain, Netherlands, Belgium, United Kingdom, Denmark, Italy, Poland
Genmab

Terminated

Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy

Head and Neck Cancer | Squamous Cell Carcinoma

United Kingdom, Belgium, France
Genmab

Completed

Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Head and Neck Cancer

United Kingdom, Belgium, Slovakia, Hungary
Genmab

Terminated

GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors

Renal Cell Carcinoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Urothelial Cancer

United States, United Kingdom, Spain
Genmab

Completed

Zalutumumab in Head and Neck Cancer

Head and Neck Neoplasms

Denmark, Sweden
Genmab

Terminated

Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer

Head and Neck Cancer | Squamous Cell Cancer

Belgium, Sweden, United States, France, Netherlands
Genmab

Terminated

Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer

Non Small Cell Lung Cancer

Belgium, United States, France, Netherlands, United Kingdom
Genmab

Withdrawn

Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors

Non-small Cell Lung Cancer
Genmab

Terminated

Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker

Rheumatoid Arthritis

United States, Canada
Genmab

Completed

Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.

Cutaneous T-Cell Lymphoma

United Kingdom, Germany, United States, Sweden
Genmab

Completed

Zalutumumab in Patients With Non-curable Head and Neck Cancer

Head and Neck Cancer | Squamous Cell Cancer

Sweden, United Kingdom, France, Hungary, Canada, Brazil, Belgium, Lithuania, Russian Federation, Serbia, Estonia, Poland
AbbVie
Genmab

Recruiting

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1)

Follicular Lymphoma (FL)

Austria, Greece, Israel, Korea, Republic of, Spain, Hungary, Sweden, Switzerland, France, Poland, Taiwan, Australia, Denmark, New Zealand, Turkey, Italy, Netherlands, Belgium, Canada, South Africa, Czechia, Brazil, Germany, Argentina, United... and more
AbbVie
Genmab

Recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma

United States, France, Israel, Korea, Republic of, Spain, Taiwan, Netherlands, Czechia, Japan, Hungary, Germany, Denmark
AbbVie
Genmab

Recruiting

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

Non-hodgkin Lymphoma

United States, Australia, France, Israel, Korea, Republic of, Spain, Taiwan, Japan, Italy, Belgium, Germany, Canada, Turkey, Czechia
Genmab
AbbVie

Recruiting

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE™ CLL-1)

Small Lymphocytic Lymphoma | Richter's Syndrome | Relapsed/Refractory Chronic Lymphocytic Leukemia

United States, Belgium, Netherlands, Spain, Italy, Australia, Israel, France, Denmark, Czechia, Germany, United Kingdom
Genmab
AbbVie

Active, not recruiting

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE™ NHL-1)

Small Lymphocytic Lymphoma (SLL) | DLBCL | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | MCL | Marginal Zone Lymphoma (MZL) | High-grade B-cell Lymphoma (HGBCL) | FL

Korea, Republic of, United States, Australia, Singapore, Netherlands, Sweden, France, Finland, United Kingdom, Spain, Germany, Denmark, Italy, Poland, Canada
AbbVie
Genmab

Active, not recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma

B-Cell Non-Hodgkin Lymphoma

China
Genmab
AbbVie

Terminated

First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Small Lymphocytic Lymphoma | High-grade B-cell Lymphoma | Primary Mediastinal Large B-cell Lymphoma

United States, Spain, Netherlands, Belgium, France, Denmark
Genmab
AbbVie

Terminated

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

Esophageal Cancer | Prostate Cancer | Bladder Cancer | Non-small Cell Lung Cancer (NSCLC) | Uterine Cancer | Triple Negative Breast Cancer (TNBC) | Squamous Cell Carcinoma of Head and Neck (SCCHN) | Locally Advanced or Metastatic Solid Tumor(s)

Spain, Israel, United States, Denmark
AbbVie
Genmab

Recruiting

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

Follicular Lymphoma (FL)

United States, Puerto Rico
Genmab
AbbVie

Recruiting

Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-3)

Diffuse Large B Cell Lymphoma

France, Korea, Republic of, Spain, Belgium, Japan, Germany, Czechia, United Kingdom, Italy, Austria, United States, Poland
AbbVie
Genmab

Recruiting

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)

Diffuse Large B-Cell Lymphoma

Korea, Republic of, Spain, Japan, Israel, Australia, Poland, Netherlands, Sweden, Greece, Taiwan, Italy, Belgium, Denmark, Switzerland, France, Bulgaria, Hungary, Austria, New Zealand, Czechia, Croatia, Brazil, China, United States, Canada and more
Genmab
AbbVie

Approved for marketing

Expanded Access Program for Epcoritamab

Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Large B-cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-cell Lymphoma (HGBCL) | Grade 3B Follicular Lymphoma
AbbVie
Genmab

No longer available

Expanded Access to Epcoritamab

Lymphoma
AbbVie
Genmab

Recruiting

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

Diffuse Large B-Cell Lymphoma | Classic Follicular Lymphoma

United States, Puerto Rico
Genmab
AbbVie

Recruiting

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (EPCORE™ NHL-2)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma

United States, France, Italy, Spain, United Kingdom, Belgium, Denmark, Netherlands, Finland, Czechia, Sweden, Australia, Norway
Genmab
AbbVie

Active, not recruiting

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL (EPCORE DLBCL-1)

Diffuse Large B-cell Lymphoma

Korea, Republic of, Spain, Taiwan, Belgium, France, Israel, United Kingdom, China, United States, Netherlands, Japan, Sweden, Turkey, Australia, Singapore, Germany, Denmark, Poland, Italy, Hungary, Austria, Russian Federation, Norway, Canad... and more
Genmab
AbbVie

Active, not recruiting

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL (EPCORE™ NHL-3)

Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma

Japan
GlaxoSmithKline
Genmab

Completed

Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)

Leukaemia, Lymphocytic, Chronic

Sweden
Seagen Inc.
Genmab

Recruiting

Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (innovaTV 301)

Cervical Cancer

United States, Canada, Japan, Austria, Belgium, China, France, Korea, Republic of, Netherlands, Singapore, Spain, United Kingdom, Argentina, Brazil, Germany, Italy, Norway, Peru, Poland, Finland, Denmark, Ireland, Czechia, Hungary, Taiwan, Swed... and more
Genmab
Seagen Inc.

Completed

A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies (innovaTV 206)

Solid Tumor

Japan
Seagen Inc.
Genmab

Completed

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

Prostate Cancer | Squamous Cell Carcinoma of the Head and Neck | Bladder Cancer | Cervix Cancer | Lung Cancer, Nonsmall Cell | Ovary Cancer | Esophagus Cancer | Endometrium Cancer

United States, United Kingdom
BioNTech SE
Genmab

Recruiting

Safety and Preliminary Efficacy of BNT314 With or Without an Immune Checkpoint Inhibitor in Cancer Patients With Malignant Solid Tumors

Advanced Malignant Solid Tumor

United States, United Kingdom
Genmab
BioNTech SE

Not yet recruiting

GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer

Advanced Endometrial Cancer

Korea, Republic of, Spain, Belgium, United States, Denmark, Italy
Genmab
BioNTech SE

Active, not recruiting

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Cervical Cancer | Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Solid Tumors | Endometrial Carcinoma | Urothelial Carcinoma

United States, Spain, Israel, Czechia, Georgia, Italy, Poland, Turkey, Hungary, Ukraine
Seagen Inc.
Genmab

Completed

A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, Spain, Belgium, Denmark, Ireland, Italy
Genmab
BioNTech SE

Recruiting

A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors

Malignant Solid Tumor

Japan
Genmab
BioNTech SE

Recruiting

A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors

Non-CNS Tumor

France
Genmab
BioNTech SE

Recruiting

GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors

Melanoma | Malignant Solid Tumor | Non Small Cell Lung Cancer (NSCLC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Head and Neck Squamous Cell Carcinoma (HNSCC) | Colorectal Cancer (CRC)

United States, Taiwan, Spain, Israel, Korea, Republic of, France, Italy, Denmark, Germany, United Kingdom, Georgia, Moldova, Republic of
Genmab
BioNTech SE

Active, not recruiting

Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors

Solid Tumor, Adult

Spain, Georgia, Moldova, Republic of
Genmab
BioNTech SE

Active, not recruiting

A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy

Solid Tumor, Adult

Spain, United States
Genmab
BioNTech SE

Active, not recruiting

GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies

Solid Tumor

Japan
Seagen Inc.
Genmab

Completed

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Bladder Cancer | Cervix Cancer | Ovary Cancer | Esophagus Cancer | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Endometrium Cancer | Prostate Cancer (CRPC) | Lung Cancer(NSCLC)

United States, Belgium, United Kingdom, Denmark, Sweden
Seagen Inc.
Genmab

Completed

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Bladder Cancer | Cervix Cancer | Ovary Cancer | Esophagus Cancer | Endometrium Cancer | Prostate Cancer (CRPC) | Lung Cancer (NSCLC)

United States, United Kingdom, Belgium, Hungary, Denmark

Clinical Trials Sponsored by Genmab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations